TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ENDRA Life Sciences ( (NDRA) ) has issued an announcement.
On June 11, 2025, ENDRA Life Sciences Inc. shared an investor presentation on its website, detailing a new business strategy previously announced on March 31, 2025. This strategic update is part of the company’s ongoing efforts to enhance its market positioning and operational effectiveness.
The most recent analyst rating on (NDRA) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on ENDRA Life Sciences stock, see the NDRA Stock Forecast page.
Spark’s Take on NDRA Stock
According to Spark, TipRanks’ AI Analyst, NDRA is a Underperform.
ENDRA Life Sciences is currently facing significant financial and operational challenges, with no revenue generation and persistent losses. Despite some short-term technical momentum, the lack of profitability and unattractive valuation metrics weigh heavily on the stock’s potential. Immediate improvements in financial performance and strategic direction are crucial for enhancing its outlook.
To see Spark’s full report on NDRA stock, click here.
More about ENDRA Life Sciences
Average Trading Volume: 171,720
Technical Sentiment Signal: Sell
Current Market Cap: $2.58M
See more insights into NDRA stock on TipRanks’ Stock Analysis page.